Wilmington, Delaware, Sept. 25, 2024 (GLOBE NEWSWIRE) — Allied Market Research published a report, titled, “Deferasirox Market by Product Type (90 mg, 125 mg, 250 mg, 360 mg and Others), Application (Transfusional Iron Overload and NTDT Caused Iron Overload), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Providers): Global Opportunity Analysis and Industry Forecast, 2024-2033″. According to the report, the deferasirox market was valued at $2.9 billion in 2023, and is estimated to reach $4.6 billion by 2033, growing at a CAGR of 4.7% from 2024 to 2033. 

Prime determinants of growth

Increase in prevalence of iron overload disorders, increase in research and development activities, and rise in awareness and screening programs are the major factors that drive the deferasirox market growth. However, the side effects associated with drug may restricts the market growth. Moreover, growth avenues in emerging markets offer remunerative opportunities for the expansion of the global deferasirox market.   

Request Sample of the Report on Deferasirox Market Forecast 2033 – https://www.alliedmarketresearch.com/request-sample/A324400 

Report coverage & details

Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/A324400 

Segment Highlights  

Rise in demand for diverse deferasirox dosages 

By product type, the others segment is driven by the rise in demand for deferasirox dosages due to its efficacy in treating chronic iron overload in patients with transfusion-dependent anemias. In addition, advancements in pharmaceutical formulations have enhanced patient compliance and therapeutic outcomes. Furthermore, increased awareness and diagnosis of iron overload disorders, along with expanded healthcare access in emerging markets contributes towards the segment growth.  

Rise in demand for deferasirox technology in transfusional iron overload  

By application, the transfusional iron overload segment is driven by the growing prevalence of chronic conditions such as thalassemia and sickle cell anemia, which require frequent transfusions and thus pose a risk of iron overload. Additionally, advancements in treatment protocols and increasing awareness among healthcare providers contribute to segment growth. The transfusional iron overload segment is expected to see substantial market expansion owing to rise in incidence of transfusion-dependent anemias.  

Rise in adoption of deferasirox in retail pharmacies  

By distribution channel, the retail pharmacies segment held a substantial portion of the deferasirox market share, primarily driven by their accessibility and convenience for patients. Retail pharmacies offer direct, over-the-counter access to deferasirox, facilitating prompt treatment for chronic iron overload conditions. Their widespread presence ensures that patients can easily obtain their prescriptions without extensive wait times. The segment’s growth is further supported by increasing patient preference for convenient access to medications and the expanding network of retail pharmacies globally. This makes retail pharmacies a key distribution channel in the deferasirox market.  

For Purchase Related Queries/Inquiry – https://www.alliedmarketresearch.com/purchase-enquiry/A324400 

Regional Outlook  

North America Dominance by 2033  

North America is expected to maintain its leadership in the deferasirox market owing to a well-established healthcare infrastructure and advanced medical research capabilities, which facilitate the development and distribution of deferasirox. In addition, rise in prevalence of conditions requiring iron chelation therapy is driving the demand for deferasirox. Furthermore, the presence of major pharmaceutical companies and increased awareness and better diagnostic capabilities contribute to higher rates of diagnosis and treatment, which thereby drives the market growth in this region.  

Key Players  

• Dr. Reddy’s Laboratories, Inc.  

• Teva Pharmaceutical Industries Ltd.  

• Sun Pharmaceutical Industries Ltd.  

• Glenmark Pharmaceuticals Inc.  

• Taj Pharmaceuticals Limited  

The report provides a detailed analysis of these key players in the global deferasirox market. These players have adopted different strategies such as agreement, product appeoval, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.   

Get Customized Reports with your Requirements – https://www.alliedmarketresearch.com/request-for-customization/A324400 

Recent Developments in Deferasirox Industry  

• In June 2020, Zydus Cadila received the final approval from the U.S. FDA to market Deferasirox Tablets in the strengths of 90 mg, 180 mg and 360 mg.   

Trending Reports in Healthcare Industry:  

Point of Care Diagnostics Market – Global Opportunity Analysis and Industry Forecast, 2023-2032 

Contraceptives Market – Global Opportunity Analysis and Industry Forecast, 2023-2032 

Electrophysiology Market – Global Opportunity Analysis and Industry Forecast, 2023-2032 

Orphan Drugs Market – Global Opportunity Analysis and Industry Forecast, 2023-2032 

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research: 

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. 

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access 

About Allied Market Research: 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI. 

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.  

Contact 

David Correa 

1209 Orange Street, 

Corporation Trust Center, 

Wilmington, New Castle, 

Delaware 19801 USA. 

Toll Free: +1-800-792-5285 

Int’l: +1-503-894-6022 

UK: +44-845-528-1300 

Hong Kong: +852-301-84916 

India (Pune): +91-20-66346060 

Fax: +1-855-550-5975 

help@alliedmarketresearch.com   

Web: https://www.alliedmarketresearch.com    

Follow Us on: LinkedIn Twitter